secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0001104659-22-099017
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics appoints Ryan Maynard as CFO, effective Sept 12, 2022
-----------------------------------------------------------------------

- Ryan Maynard appointed CFO effective September 12, 2022; principal financial and accounting officer.
- Compensation: $460,000 base salary, 40% target bonus, 225,000 share option grant vesting over 4 years.
- Maynard previously CFO of LetsGetChecked and Rigel Pharmaceuticals (10 years as CFO at Rigel).
- Appointment aligns with ongoing launch of KORSUVA injection for chronic pruritus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465922099017/0001104659-22-099017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465922099017/tm2225550d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-099017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer